Results 261 to 270 of about 245,414 (303)
Some of the next articles are maybe not open access.
To bet or not to bet? The coding of bets modulates brain potentials in outcome evaluations
NeuroReport, 2015Decisions made on the basis of risk often require rapid evaluation of feedback before follow-up actions and feedback-related negativity in brain potential is sensitive to the poor outcome. The current study investigated the effects of feedback from one's own decision (Experiment 1) and feedback from observing others' decisions (Experiment 2) on ...
Yaozhong, Liu +3 more
openaire +2 more sources
Bet Shemesh, Ramat Bet Shemesh (B)
Hadashot Arkheologiyot - Excavations and Surveys in Israel, 2012During April 2012, a trial excavation was conducted in Ramat Bet Shemesh (Permit No. A-6484; map ref. 199874-920/623608-39), prior to construction. The excavation, undertaken on behalf of the Israel Antiquities Authority and underwritten by the Ministry of Construction and Housing,
openaire +1 more source
Communications of the ACM, 2009
Advanced computational models are enabling researchers to create increasingly sophisticated prediction markets.
openaire +2 more sources
Advanced computational models are enabling researchers to create increasingly sophisticated prediction markets.
openaire +2 more sources
Synthese, 2004
In the Sleeping Beauty problem, Beauty is uncertain whether the outcome of a certain coin toss was heads or tails. One argument suggests that her degree of belief in heads should be 1/3, while a second suggests that it should be 1/2. Prima facie, the argument for 1/2 appears to be stronger. I offer a diachronic Dutch Book argument in favor of 1/3. Even
openaire +3 more sources
In the Sleeping Beauty problem, Beauty is uncertain whether the outcome of a certain coin toss was heads or tails. One argument suggests that her degree of belief in heads should be 1/3, while a second suggests that it should be 1/2. Prima facie, the argument for 1/2 appears to be stronger. I offer a diachronic Dutch Book argument in favor of 1/3. Even
openaire +3 more sources
Science, 2003
We depend on the efficiency of our adaptive immune system to combat pathogen invaders. Part of this protective response includes development of CD4 and CD8 effector T cells. As Hatton and Weaver discuss in their Perspective, key transcription factors regulating CD4 effector T cell development have been identified, whereas those governing the ...
Robin D. Hatton, Casey T. Weaver
openaire +1 more source
We depend on the efficiency of our adaptive immune system to combat pathogen invaders. Part of this protective response includes development of CD4 and CD8 effector T cells. As Hatton and Weaver discuss in their Perspective, key transcription factors regulating CD4 effector T cell development have been identified, whereas those governing the ...
Robin D. Hatton, Casey T. Weaver
openaire +1 more source
BMJ, 2009
New websites in the US are encouraging people to make public commitments to change their behaviour.
openaire +2 more sources
New websites in the US are encouraging people to make public commitments to change their behaviour.
openaire +2 more sources
To bet or not to bet: a reality check for tennis betting market efficiency
Applied Economics, 2017We present evidence that the tennis betting market appears to be much more efficient than suggested by previous studies. More specifically, we study the market efficiency by studying the forecasting performance of a diversified set of 40 betting rules in two ways: by searching for the existence of a return differential between betting rules and by ...
Štefan Lyócsa, Tomáš Výrost
openaire +1 more source
Bet Shemesh, Ramat Bet Shemesh (B)
Hadashot Arkheologiyot - Excavations and Surveys in Israel, 2015In September 2014, a trial excavation was conducted in Ramat Bet Shemesh (Permit No. A-7217; map ref. 197623-874/623013-172; Fig. 1), prior to construction. The excavation, undertaken on behalf of the Israel Antiquities Authority and financed by the Ministry of Construction and
openaire +1 more source
Nature Biotechnology, 2001
With patents on several blockbuster therapeutic proteins soon to expire and several companies pondering whether to manufacture their own versions of these medicines, can a commercially viable business be based on biogenerics?
openaire +2 more sources
With patents on several blockbuster therapeutic proteins soon to expire and several companies pondering whether to manufacture their own versions of these medicines, can a commercially viable business be based on biogenerics?
openaire +2 more sources
BETting on the future: BET inhibition for patients with lymphoma
MedDespite available treatments, patients with lymphoma may still develop relapsed or refractory diseases, highlighting the need for new therapies. Zhang et al.1 report a phase I dose-escalation study of TQB3617, a novel BET inhibitor, in diverse lymphoma subtypes.
Timothy J, Voorhees, Catherine C, Coombs
openaire +2 more sources